> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Cabiralizumab Phase 2 Trial Misses Endpoint
- URL: https://www.fdaweb.com/cabiralizumab-phase-2-trial-misses-endpoint/
- Published: 2020-02-20T12:00:00.000Z
- Updated: 2026-09-14T16:03:49.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5146132

Bristol-Myers Squibb says that a Phase 2 trial testing the combination of Five Prime Therapeutics’ cabiralizumab and Opdivo (nivolumab) with and without chemotherapy in patients with advanced pancreatic cancer did not meet its primary endpoint. A Five Prime [statement](https://www.businesswire.com/news/home/20200218005144/en/Prime-Therapeutics-Update-Phase-2-Trial-Cabiralizumab?ref=fdaweb.com) says that the trial enrolled some 160 patients with locally advanced or metastatic pancreatic cancer that has progressed during or after one line of chemotherapy.

BMS says it has no near-term plans for additional sponsored development of cabiralizumab but will continue to support its evaluation in select, ongoing investigator-sponsored trials and may continue to assess future development opportunities for it. It said that no safety signals were observed in the Phase 2 trial.

Cabiralizumab is described as an investigational antibody that inhibits the CSF-1 receptor and has been shown in preclinical models and clinical studies to block the activation and survival of monocytes and macrophages.